Key Insights

Highlights

Success Rate

89% trial completion (above average)

Published Results

38 trials with published results (24%)

Research Maturity

101 completed trials (64% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

7.5%

12 terminated out of 159 trials

Success Rate

89.4%

+2.9% vs benchmark

Late-Stage Pipeline

28%

44 trials in Phase 3/4

Results Transparency

38%

38 of 101 completed with results

Key Signals

38 with results89% success12 terminated

Data Visualizations

Phase Distribution

119Total
Not Applicable (46)
Early P 1 (1)
P 1 (10)
P 2 (18)
P 3 (27)
P 4 (17)

Trial Status

Completed101
Unknown16
Terminated12
Recruiting10
Withdrawn10
Not Yet Recruiting4

Trial Success Rate

89.4%

Benchmark: 86.5%

Based on 101 completed trials

Clinical Trials (159)

Showing 20 of 20 trials
NCT07325240Phase 4RecruitingPrimary

24-hour Effect of Rocklatan Compared With Latanoprost in Open Angle Glaucoma and Ocular Hypertension Patients

NCT07082816Phase 3Completed

Reformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction

NCT06230393TerminatedPrimary

An Extension Trial for Patients With Open-Angle Glaucoma Who Participated in the DF6-CL-20-01 Protocol.

NCT05273385Not ApplicableTerminated

Efficacy of the Nanodropper Device on Intraocular Pressure in Patients With Glaucoma

NCT06851546Not ApplicableCompletedPrimary

Efficacy of Selective Laser Trabeculoplasty Targeting Nasal Versus Inferior 180-degree

NCT05506423Enrolling By InvitationPrimary

Study of the CycloPen Micro-Interventional System and Long-Term Clinical Outcomes

NCT06246136Not ApplicableRecruitingPrimary

Comparative Effectiveness and Safety of ELIOS in Patients With Open-Angle Glaucoma Undergoing Cataract Surgery

NCT04060758Phase 1CompletedPrimary

Open Label, Sequential-dose Study of PA5108 Latanoprost FA SR Ocular Implant for Mild-moderate Glaucoma

NCT06441643Phase 2CompletedPrimary

Next Generation Rocklatan

NCT07228221Phase 4RecruitingPrimary

Standalone iStent Infinite and iDose TR for Management of Moderate to Severe Open Angle Glaucoma

NCT05938699Phase 2CompletedPrimary

Aqueous Humor Dynamics of NCX 470 Ophthalmic Solution

NCT04630808Phase 3CompletedPrimary

MRCT Evaluating NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension

NCT03750201Not ApplicableCompletedPrimary

A Study to Assess an Automated Laser Device for Direct Selective Laser Trabeculoplasty

NCT04445519Phase 3CompletedPrimary

Phase 3 Trial of NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension

NCT05035394Not ApplicableActive Not RecruitingPrimary

Swedish Microinvasive Glaucoma Surgery Study (SMIGS)

NCT06993311Completed

Real World Evidence of Xen45 Gel Implant in Pseudoexfoliation Glaucoma

NCT04773106Not ApplicableCompleted

Long-term Safety and Performance of the ARGOS-SC Suprachoroidal Pressure Sensor System in Patients With Glaucoma Underwent Non-penetrating Glaucoma Surgery

NCT03047239Not ApplicableWithdrawnPrimary

TF for the Prediction of Visual Field Progression

NCT06883123Phase 4RecruitingPrimary

Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost

NCT06523751Not ApplicableRecruitingPrimary

Trabeculopuncture as Predictive Test for the Success of Ab Interno Trabeculectomy

Scroll to load more

Research Network

Activity Timeline